陈康;焦建宝;陈涛平;薛金伟;侯煜;姜源涛;任俏;

• 1:河北大学附属医院骨二科
• 2:河北大学附属医院风湿免疫科

摘要(Abstract)：

[目的]探讨人参皂苷CK对人骨肉瘤细胞MG-63的凋亡诱导作用及其具体作用机制。[方法] MG-63细胞分为空白对照组和CK药物处理组。采用MTT法检测细胞活性及增殖能力,倒置显微镜下观察细胞凋亡形态。细胞凋亡形态检测、Hoechst细胞核染色及Annexin V/PI细胞凋亡实验检测药物CK对细胞的诱导凋亡作用;Western blotting检测凋亡相关蛋白Caspase-9、Bcl-2及BAX的表达,研究其具体凋亡机制。[结果] CK能够显著降低MG-63的体外活性及生存率(P<0.05);细胞凋亡形态检测、Hoechst细胞核染色及Annexin V/PI细胞凋亡实验证明CK可诱导MG-63凋亡(P<0.05);CK处理后MG-63细胞表达的Caspase-9及BAX表达上调,相反Bcl-2表达下调(P<0.05)。[结论]人参皂苷CK对人骨肉瘤细胞MG-63具有凋亡诱导作用,而以Caspase-9为关键因素的线粒体凋亡途径在此凋亡中起着决定性作用。

关键词(KeyWords)： 人参皂苷CK;骨肉瘤细胞MG-63;凋亡

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈康;焦建宝;陈涛平;薛金伟;侯煜;姜源涛;任俏;

Email:

DOI:

参考文献(References)：

• [1]Luetke A,Meyers PA,Lewis I,et al.Osteosarcoma treatmentwhere do we stand?A state of the art review[J].Cancer Treat Rev,2014,40(4):523-532.
• [2]Isakoff MS,Bielack SS,Meltzer P,et al.Osteosarcoma:current treatment and a collaborative pathway to success[J].J Clin Oncol,2015,33(27):3029-3035.
• [3]Kovar H.Selective enhancer changes in osteosarcoma lung metastasis[J].Nat Med,2018,24(2):126-127.
• [4]Siddiqui YS,Sherwani MK,Khan AQ,et al.Neglected orthopedic oncology:causes,epidemiology and challenges for management in developing countries[J].Indian J Cancer,2015,52(3):325-329.
• [5]Isakoff MS,Bielack SS,Meltzer P,et al.Osteosarcoma:current treatment and a collaborative pathway to success[J].J Clin Oncol,2015,33(27):3029-3035.
• [6]Hattinger CM,Fanelli M,Tavanti E,et al.Advances in emerging drugs for osteosarcoma[J].Expert Opin Emerg Drugs,2015,20(3):495-514.
• [7]Liu Y,Wang W,XU J,et al.Dihydroartemisinin inhibits tumor growth of human osteosarcoma cells by suppressing Wnt/betacatenin signaling[J].Oncol Rep,2013,30(4):1723-1730.
• [8]Ando K,Heymann MF,Stresing V,et al.Current therapeutic strategies and novel approaches in osteosarcoma[J].Cancers,2013,5(2):591-616.
• [9]Bae MY,Cho JH,Choi IS,et al.Compound K,a metabolite of ginsenosides,facilitates spontaneous GABA release onto CA3 pyramidal neutons[J].J Neurochem,2010,114:1085-1096
• [10]Kim JS,Kim Y,Han SH,et al.Development and validation of an LC-MS/MS method for determination of compound K in human plasma and clinical application[J].J Ginseng Res,2013,37(1):135-141.
• [11]Chen XJ,Liu WJ,Wen ML,et al.Ameliorative effects of compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats[J].Sci Rep,2017,7:41144.
• [12]Zhang Z,Du GJ,Wang CZ,et al.Compound K,a ginsenoside metabolite,inhibits colon cancer growth via multiple pathways including p53-p21 interactions[J].Int J Mol Sci,2013,14(2):2980-95.
• [13]Wei S,Li Wl,Yu Y,et al.Ginsenoside compound K suppresses the hepatic gluconeogenesis via activating adenosine-5′monophosphate kinase:a study in vitro and in vivo[J].Life Sci,2015,139:8-15.
• [14]Zhang GM,Zhu T,Chen GH,et al.The efect of ginsenoside compound K on the formation of atherosclerosis[J].J Cadiovascular Pulmonary Dis,2017,5(36):408-413.
• [15]Li XC,Zhang XY,Xu S,et al.Establishment of C57BL/6J mouse nonalcoholic fatty liver model[J].Chin J Veter Med,2013,1(49):6-8.
• [16]Li Y,Zhou T,Ma C,et al.Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells[J].J Thoracic Dis,7(3):400-406.
• [17]Wei S,Li W,Yu Y,et al.Ginsenoside compound K suppresses the hepatic gluconeogenesis via activating adenosine-5′monophosphate kinase:a study in vitro and in vivo[J].Life Sci,139,8-15.
• [18]Yang L,Xin J,Zhang Z,et al.TPGS-modified liposomes for the delivery of ginsenoside compound K against non-small cell lung cancer:formulation design and its evaluation in vitro and in vivo[J].J Pharmacy Pharmacol,68(9):1109-1118.
• [19]Zhang K,Li,K.Effects of ginsenoside compound K combined with cisplatin on the proliferation,apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer[J].Pharmaceutical Biol,54(4):561-568.
• [20]Hu Q,Wu D,Chen W,et al.Molecular determinants of caspase-9activation by the Apaf-1 apoptosome[J].Proc Natl Acad Sci U SA,2014,111(46):16254-16261.
• [21]Jin Z,El-Deiry WS.Overview of cell death signaling pathways[J].Cancer Biol Ther,2014,4(2):147-171.
• [22]Luo X,Budihardjo I,Zou H,et al.Bid,a Bcl2 interacting protein,mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors[J].Cell,1998,94(4):481-490.